SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2002, for Spherix Incorporated (formerly Biospherics Incorporated). The company operates two primary segments: InfoSpherix (information technology and reservation services) and BioSpherix (biotechnology products including FlyCracker and tagatose/Naturlose). The financial statements are unaudited.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2002 | Nine Months Ended Sept 30, 2002 | Nine Months Ended Sept 30, 2001 |
|---|---|---|---|
| Revenue | $4,832,470 | $12,125,147 | $16,853,031 |
| Net Income (Loss) | $137,096 | $(1,273,334) | $1,568,846 |
| EPS (Diluted) | $0.01 | $(0.11) | $0.14 |
| Operating Cash Flow | N/A | $(1,296,719) | $68,798 |
| Cash and Equivalents | $8,621,180 | $8,621,180 | $4,531,672 |
| Working Capital | $10,217,336 | $10,217,336 | $7,139,196 |
| Debt (Line of Credit) | $103,696 | $103,696 | $212,856 |
Material Changes vs. Prior Period
- Revenue Decline: Nine-month revenue decreased by approximately 28% ($4.7 million) compared to 2001. This was driven by a 90% drop in commercial contracts and the absence of a $1.3 million one-time settlement revenue recognized in 2001 related to a Department of Labor dispute.
- Profitability Shift: The company swung from a net income of $1.57 million in the prior nine-month period to a net loss of $1.27 million. InfoSpherix, previously profitable, reported an operating loss of $213,000 for the nine months.
- Expense Increases: Research and Development (R&D) expenses increased 126% year-over-year due to pilot plant studies for Naturlose and legal costs associated with arbitration against a tagatose licensee. Selling, General, and Administrative (SG&A) expenses decreased due to a reclassification of IT costs to direct operating costs.
- Liquidity Improvement: Despite operating losses, cash balances increased by $2.0 million, primarily due to $3.9 million in proceeds from the exercise of warrants and issuance of common stock.
Outlook, Risks, and Management Commentary
- Guidance: Management anticipates operating at a loss in the fourth quarter of 2002 due to seasonal slowdowns in the reservation business. The magnitude of the loss depends on securing new commercial contracts.
- BioSpherix Strategy: The company is increasing investment in BioSpherix, specifically tagatose and Naturlose. A joint venture for tagatose production is expected to commence sales by mid-2003. The company is exploring licensing FlyCracker to a third party rather than continuing direct sales.
- Legal Contingency: In May 2002, Spherix initiated arbitration against MD Foods amba (Arla Foods) regarding delays in commercializing tagatose. The company seeks damages and acceleration of commercialization.
- Capital Resources: The company maintains a $2.0 million line of credit with Bank of America, with $104,000 outstanding. Management believes current funds are sufficient to meet obligations and fund capital needs, including potential pilot plant construction.
Investor Verification Checklist
- Revenue Sustainability: Verify the status of new government contracts (Indiana DNR, OPM, HUD) mentioned as starting in Q4 to offset the seasonal decline.
- Arbitration Outcome: Monitor the progress of the arbitration against Arla Foods, as potential damages or accelerated royalties could materially impact future revenue.
- BioSpherix Commercialization: Confirm timelines for the tagatose joint venture sales (expected mid-2003) and the decision regarding FlyCracker licensing vs. direct sales.
- Debt Covenants: Review compliance with the Bank of America line of credit covenants, specifically tangible net worth ratios, given the recent operating losses.
- One-Time Items: Ensure future comparisons exclude the $1.3 million 2001 settlement revenue to accurately assess organic growth trends.